MedTrace Logo

The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI

NCT06907693 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2026-04-13

No results posted yet for this study

Summary

Explore the impact of drug candidate CS1 on pathological vascular remodeling of small pulmonary arteries in the disease pulmonary arterial hypertension (PAH). This sub-study for CS1-004 aims to utilize FRI, an innovative, non-invasive imaging technology to visualize how long-term use of CS1 influences structural changes in pulmonary arteries. This sub-study seeks to provide valuable insights into the potential of CS1 to transform PAH treatment in some patients enrolled in the Expanded Access Program (CS1-004).

Conditions

Interventions

DIAGNOSTIC_TEST

CT Pulmonary Angiography Scan

Computed tomography (CT) pulmonary angiography scan of the chest with IV contrast

Sponsors & Collaborators

  • Cereno Scientific AB

    collaborator INDUSTRY

  • Prisma Health-Upstate

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-14
Primary Completion
2025-12-04
Completion
2026-04-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06907693 on ClinicalTrials.gov